Trial Profile
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dianhydrogalactitol (Primary)
- Indications Brain cancer; Glioblastoma; Glioma
- Focus Adverse reactions
- Sponsors Del Mar Pharmaceuticals
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2016 Status changed from active, no longer recruiting to completed, according to a DelMar Pharmaceuticals media release.